Pentosan Polysulfate
Status
FDA-approved. FDA-approved labeling exists as Elmiron for the relief of bladder pain or discomfort associated with interstitial cystitis. The label carries warnings covering retinal pigmentary changes with long-term use, along with bleeding risk given the compound's weak anticoagulant activity, and advises ophthalmologic examination.
What it is
An approved bladder medicine also used off-label for joint discomfort.
What published research measured
A semi-synthetic polysulfated xylan given orally, and one of the few compounds in this category with a full approval behind it. Its trial history in interstitial cystitis is mixed — several randomized trials reported modest benefit over placebo and others found little separation — which is why the evidence tier here is not higher. The finding that has changed clinical practice around this drug is a safety one: a distinctive pigmentary maculopathy associated with long-term use was first described in 2018 and has since been replicated in multiple independent cohorts, with risk rising with cumulative exposure. Vision changes on this compound are not a minor complaint, and the approved labeling was updated to reflect the retinal risk.
Source
FDA labeling for Elmiron (pentosan polysulfate sodium) · Pearce et al. 2018, Ophthalmology — pigmentary maculopathy associated with pentosan polysulfate
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.